Azadirachta indica treatment on the congenital malformations of fetuses from rats

被引:20
作者
Dallaqua, Bruna [1 ]
Saito, Felipe Hiroshi [1 ]
Rodrigues, Tiago [2 ]
Paranhos Calderon, Iracema Mattos [1 ]
Cunha Rudge, Marilza Vieira. [1 ]
Volpato, Gustavo Tadeu [3 ]
Damasceno, Debora Cristina [1 ]
机构
[1] UNESP Univ Estadual Paulista, Botucatu Med Sch, Grad Program Gynecol Obstet & Mastol, Dept Gynecol & Obstet,Lab Expt Res Gynecol & Obst, Botucatu, SP, Brazil
[2] Fed Univ ABC, Sao Paulo, Brazil
[3] Mato Grosso Fed Univ UFMT, Univ Ctr Araguaia, Inst Biol & Hlth Sci, Barra Do Garcas, Mato Grosso, Brazil
基金
巴西圣保罗研究基金会;
关键词
Azadirachta indica; Neem; Pregnancy; Rat; Anomaly; POLYUNSATURATED FATTY-ACIDS; VOLATILE FRACTION; NEEM OIL; PREGNANCY; STREPTOZOTOCIN; TOXICITY; EXTRACTS; PRANEEM; MICE;
D O I
10.1016/j.jep.2013.10.046
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Ethnopharmacological relevance: Azadirachta indica A. Juss, popularly known as neem, presents medicinal and insecticide properties. However, the repercussions of the neem maternal treatment on fetal development should be investigated. Thus, the aim of this study was to evaluated the effects of Azadirachta indica (neem) on the frequency of congenital malformations in fetuses from rats. Materials and methods: Pregnant rats were randomly distributed into three experimental groups: NT=non-treated; TOil=treated with neem seed oil (1.2 mL/day); TAP=treated with active principle of Azadirachta indica (azadirachtin-1.0 mg/mL/day). The neem oil (1.2 mL/day) or azadirachtin (1.0 mg/mL/day) treatments were orally administered throughout pregnancy. Blood samples were collected on days 0, 7, 14 and 20 of pregnancy Oral glucose test tolerance (OGTT) was performed at day 17 of pregnancy for estimation of total area under the curve (AUC). At term, the fetuses were collected and external and internal (visceral and skeletal) malformations were analyzed. Results: The data showed that the dams treated with neem seed oil and Azadirachtin had no significant change in glucose levels and AUC. It was also verified that neem oil treatment contributed to increase the frequency of malformation/variation, in particular the visceral in their fetuses, while neither significant result was observed in TAP group. Conclusion: In conclusion, neem seed oil treatment administered during pregnancy caused abnormalities in rat fetuses, showing teratogenic effect but the Azadirachtin (active principle) presented no impairment in the fetuses. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:1109 / 1113
页数:5
相关论文
共 36 条
  • [11] Congenital anomalies in diabetic pregnancy
    Eriksson, Ulf J.
    [J]. SEMINARS IN FETAL & NEONATAL MEDICINE, 2009, 14 (02) : 85 - 93
  • [12] Protective role of extracts of neem seeds in diabetes caused by streptozotocin in rats
    Gupta, S
    Kataria, M
    Gupta, PK
    Murganandan, S
    Yashroy, RC
    [J]. JOURNAL OF ETHNOPHARMACOLOGY, 2004, 90 (2-3) : 185 - 189
  • [13] Relationship Between Serum Polyunsaturated Fatty Acids and Pregnancy in Women Undergoing In Vitro Fertilization
    Jungheim, Emily S.
    Frolova, Antonina I.
    Jiang, Hui
    Riley, Joan K.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (08) : E1364 - E1368
  • [14] Khosla P., 2000, Indian Journal of Physiology and Pharmacology, V44, P69
  • [15] LAI S M, 1990, SMJ Singapore Medical Journal, V31, P463
  • [16] Meliacinolin: A Potent α-Glucosidase and α-Amylase Inhibitor Isolated from Azadirachta indica Leaves and in Vivo Antidiabetic Property in Streptozotocin-Nicotinamide-Induced Type 2 Diabetes in Mice
    Martha Perez-Gutierrez, Rosa
    Damian-Guzman, Monica
    [J]. BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2012, 35 (09) : 1516 - 1524
  • [17] Inflammation and pregnancy: the role of the immune system at the implantation site
    Mor, Gil
    Cardenas, Ingrid
    Abrahams, Vikki
    Guller, Seth
    [J]. REPRODUCTIVE SCIENCE, 2011, 1221 : 80 - 87
  • [18] Purified neem (Azadirachta indica) seed extracts (Praneem) abrogate pregnancy in primates
    Mukherjee, S
    Lohiya, NK
    Pal, R
    Sharma, MG
    Talwar, GP
    [J]. CONTRACEPTION, 1996, 53 (06) : 375 - 378
  • [19] Mukherjee S, 1996, AM J REPROD IMMUNOL, V35, P51
  • [20] Othman F, 2012, CELL J, V14, P53